Displaying 84 (all) recruiting clinical trials.
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
DAY101 is an oral, selective, small-molecule, Type II pan-RAF kinase inhibitor that is being developed by DOT Therapeutics-1 Inc. (Day One, the Sponsor) for the ...Phase
Interventional
-
Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations (IND 156083)
A Phase II randomized trial will be initiated to evaluate efficacy of FGF-2 in treatment of chronic non-healing tympanic membrane perforation. This study is a ...Phase
Interventional
-
A Phase 2 Open-Label Multicenter Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
This is a Phase 2, global, multicenter, open-label, cohort study designed to evaluate the antitumor activity, safety and tolerability, HRQoL, PK, and pharmacodynamics of ALKS ...Phase
Interventional
-
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. At least 500 eligible patients will ...Phase
Interventional
-
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that ...Phase
Interventional
-
Interventional randomized double-blind parallel-group placebo-controlled multi-centre study to assess the efficacy safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy
This is a phase II, interventional, randomized, double-blind, parallel-group, placebocontrolled, multi-centre study of the efficacy (slowing disease progression), safety, and tolerability of Lu AF82422 in ...Phase
Interventional
-
A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.
Subjects will be evaluated during a screening period of 42 days. Screening laboratory evaluations and disease activity assessments will be performed by the Investigator and ...Phase
Interventional
-
ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Site for This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction ...Phase
Interventional
-
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
This is a prospective, randomized, placebo-controlled, multicenter study of patients with newly diagnosed glioblastoma (nGBM) to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide ...Phase
Interventional
-
A Phase 2a Multicenter Randomized Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.
This is a Phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept (POC) clinical study designed to evaluate the efficacy and safety of combination therapy with ...Phase
Interventional
